<SEC-DOCUMENT>0001628280-22-013956.txt : 20220512
<SEC-HEADER>0001628280-22-013956.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512080047
ACCESSION NUMBER:		0001628280-22-013956
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		22915766

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20220512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8a82036e-c8b1-4aea-9b6e-232a1886b11a,g:b5d90bc6-920a-4dc4-9b65-22e0889bdd64,d:ae4ee720d3eb42deb033a9345b031cdc--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20220512</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY180L2ZyYWc6MjEyMTU5MmI5YTk0NDc5MzkyODk4YmVhZDc4ZThiNGIvdGFibGU6MGEzNDlmMjU2NTM4NDQ3MWE2ZGU2NjAyODVjYjQ2MTcvdGFibGVyYW5nZTowYTM0OWYyNTY1Mzg0NDcxYTZkZTY2MDI4NWNiNDYxN18wLTEtMS0xLTMzMTEy_70f1796f-a4b8-4743-b847-06a781846e2a">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY180L2ZyYWc6MjEyMTU5MmI5YTk0NDc5MzkyODk4YmVhZDc4ZThiNGIvdGFibGU6MGEzNDlmMjU2NTM4NDQ3MWE2ZGU2NjAyODVjYjQ2MTcvdGFibGVyYW5nZTowYTM0OWYyNTY1Mzg0NDcxYTZkZTY2MDI4NWNiNDYxN18xLTEtMS0xLTMzMTEy_83275463-635f-46c6-8e46-6c8645c2629f">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20220512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iae4ee720d3eb42deb033a9345b031cdc_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.298%"><tr><td style="width:1.0%"></td><td style="width:57.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6YWFmZDgyODNlMWRkNGM4YjhlZWQ4MGUwNDlkZDgxZmEvdGFibGVyYW5nZTphYWZkODI4M2UxZGQ0YzhiOGVlZDgwZTA0OWRkODFmYV8wLTEtMS0xLTMzMTEy_0a007099-9ea7-4cde-a28e-e0bb2d3aaeec">8-K</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Data of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8yMTg_dfb70470-de11-44fc-82fd-1d17920887c8">May 12, 2022</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.396%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6Y2Q4Y2VhODMxNzI1NDg1OTg5NDJiNzZmMzAwNGYxMzcvdGFibGVyYW5nZTpjZDhjZWE4MzE3MjU0ODU5ODk0MmI3NmYzMDA0ZjEzN18xLTAtMS0xLTMzMTEy_17e7ccc5-9752-42fc-a7e3-a4966410e006">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTAtMS0xLTMzMTEy_7f6c8c9b-bb62-4fe8-94d6-03cba294e536">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTItMS0xLTMzMTEy_b6b8c584-b2ec-4934-b3ce-93722dabe2ef">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTQtMS0xLTMzMTEy_c0f6a93f-d58e-4400-8711-41311e87200e">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8wLTAtMS0xLTMzMTEy_c53758af-a876-4ae7-ab4b-55231a56bf4a">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8wLTEtMS0xLTMzMTEy_d3a58ebb-604a-440e-8d5f-ce3740fed585">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTAtMS0xLTMzMTEy_88d392c7-f4ba-4c06-937d-01fb8e50a9b8">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTEtMS0xLTMzMTEy_05d866ee-dd72-4650-989b-df1caa052565">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTMtMS0xLTMzMTEy_8278fd03-b91b-4531-a6cf-8a9106461dad">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDYy_7a42f1db-4284-4d6b-8c4e-854c971134b5">857</ix:nonNumeric>) <ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDYz_aae65245-24ee-483d-832b-7062f15cb5a3">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY5_957a1602-3479-4493-98a6-2f341f05977c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcx_1d3b9dca-04ea-4dcd-8f00-e2ae26a8e24b">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcy_8c991615-c481-4558-ab7b-63edda2aa8e2">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY2_70ba0d4c-663c-4c62-93f6-b33e3a656dfc">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTAtMS0xLTMzMTEy_188a330f-d78f-4bf3-98b2-f03f38fdb5b9">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTItMS0xLTMzMTEy_a4286795-9e96-4931-bcac-7c2849aa5812">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTQtMS0xLTMzMTEy_dd605944-d812-4784-8000-cdc00a23691b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).          Emerging growth company&#160;<ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY3_1cbf4261-7246-4bf2-9e15-67ed2d3d17ea">&#9746;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act&#160;&#160;<ix:nonNumeric contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcz_f2183b9d-a230-4e75-ae14-1db2c1e61043">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iae4ee720d3eb42deb033a9345b031cdc_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations and Financial Condition</span></div><div><span><br/></span></div></td></tr></table></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 12, 2022, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results and other business highlights for the first quarter ended March 31, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulation FD Disclosure</span></div><div><span><br/></span></div></td></tr></table></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2022, the Company posted an updated corporate presentation on the Company&#8217;s website. To access the presentation, investors should visit the &#8220;Investors&#8221; section of the Company&#8217;s website at www.x4pharma.com.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under Item 2.02 and Item 7.01 in this Current Report of Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a991pressreleasedatedmay12.htm">Press Release of X4 Pharmaceuticals, Inc. dated May 12, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iae4ee720d3eb42deb033a9345b031cdc_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  May 12, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991pressreleasedatedmay12.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0952b3c99ed2481196753d8800680cd3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><img alt="x4logoa.jpg" src="x4logoa.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:95px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:102%">X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:102%">Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b study anticipated during 3Q 2022&#59; Waldenstr&#246;m&#8217;s macroglobulinemia Phase 1b study now fully enrolled with results expected in second half of 2022</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:102%">Conference call to be hosted today at</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:102%"> 8&#58;30 a.m. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:102%">EDT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BOSTON, Mass. &#8211; May 12, 2022 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(Nasdaq&#58; XFOR), a leader in the discovery and development of novel oral CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today reported financial results for the first quarter ended March 31, 2022. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;As we quickly approach top-line results from our 4WHIM pivotal Phase 3 trial for WHIM syndrome by the end of this year, the X4 team continues to identify and expand the breadth of individuals diagnosed with this rare disease. Initiatives aimed at supporting diagnosis and driving disease awareness, such as our PATH4WARD program offering free genetic sequencing to patients, and publishing peer-reviewed research to help define novel pathogenic genetic variants, are adding to the population of those known to be affected by WHIM and chronic neutropenia,&#8221; said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. &#8220;Specifically, to support those affected by chronic neutropenia, we are expanding the availability of genetic testing through PATH4WARD and evaluating patients with congenital, idiopathic, and cyclic chronic neutropenia in our ongoing Phase 1b study. We look forward to providing both clinical data and regulatory updates over the coming months on this important initiative.&#8221;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:102%;text-decoration:underline">Recent Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Presented posters at the CIS 2022 Annual Meeting that detailed the PATH4WARD genetic testing program to aid in the diagnosis of WHIM syndrome and chronic neutropenia, and the characterization of a novel pathogenic CXCR4 variant (S341Y).</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Presented preclinical data on mavorixafor&#8217;s ability to significantly enhance the tumor-cell killing activity of the leading commercial and clinical stage Bruton Tyrosine Kinase Inhibitors (BTKi) including ibrutinib, zanubrutinib, pirtobrutinib (LOXO-305) and nemtabrutinib (ARQ-531), at the 2022 AACR Annual Meeting.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Completed enrollment in the ongoing Phase 1b study of mavorixafor in combination with ibrutinib in patients with Waldenstr&#246;m&#8217;s Macroglobulinemia (WM) whose tumors express mutations in MYD88 and CXCR4. A total of 16 patients were enrolled and dose escalation to the 600 mg dose of mavorixafor has been completed. Results from this study are expected to be reported during the second half of 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:105%;text-decoration:underline">First Quarter 2022 Financial Results </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Cash, Cash Equivalents &#38; Restricted Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; X4 had $67.7 million </font><font style="background-color:#ffffff;color:#201f1e;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in cash, cash equivalents, and restricted cash as of March 31, 2022. The company expects that its cash and cash equivalents will fund company operations into the fourth quarter of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Research and Development (R&#38;D) Expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">were $14.1 million for the first quarter of 2022 as compared to $12.1 million for the comparable period in 2021. R&#38;D expenses include $0.7 million and $0.6 million of certain non-cash expenses for the first quarter of 2022 and 2021, respectively. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Selling, General and Administrative Expenses (SG&#38;A)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $7.7 million for the first quarter of 2022 as compared to $5.8 million for the comparable period in 2021. SG&#38;A expenses include $0.8 million and $0.7 million of certain non-cash expenses for the first quarter of 2022 and 2021, respectively. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 reported a net loss of $22.0 million for the first quarter of 2022, as compared to $18.7 million for the comparable period in 2021. Net losses include $1.5 million and $1.3 million of certain non-cash expenses for the first quarter of 2022 and 2021, respectively. </font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Conference Call and Webcast </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 will host a conference call and webcast today at 8&#58;30 am EDT to discuss financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009  internationally, followed by the conference ID&#58; 6584274. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals&#8217; website at </font><font style="color:#000099;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Following the completion of the call, a webcast replay of the conference call will be available on the website.</font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About X4 Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with rare diseases of the immune system. The company&#8217;s lead candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor&#8217;s ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, X4 believes that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID. Its efficacy and safety continue to be evaluated in a global Phase 3 clinical trial in WHIM (fully enrolled) and in two Phase 1b clinical trials &#8211; one, as monotherapy in people with chronic neutropenia, including Severe Congenital Neutropenia (SCN), and another in combination with ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (also fully enrolled). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit www.x4pharma.com.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">statements regarding the clinical development and therapeutic potential of mavorixafor and X4&#8217;s other product candidates or programs&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4&#8217;s possible exploration of additional opportunities for mavorixafor&#59; the anticipated achievement of upcoming clinical milestones&#59; the expected availability, content, and timing of clinical trial data&#59; clinical trial design, the prevalence of and market opportunity associated with WHIM and chronic neutropenia, and the company&#8217;s cash runway. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, on account of uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development&#59; the risk that trials and studies may be delayed, including, but not limited to, as a result of the effects of the ongoing COVID-19 pandemic or delayed patient enrollment, and may not have satisfactory outcomes&#59; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results&#59; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials&#59; the risk that market or prevalence estimates for WHIM and chronic neutropenia may be inaccurate and higher than the actual number of treatable patients&#59; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates&#59; the risks related to X4&#8217;s ability to raise additional capital, and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 17, 2022, and in other filings X4 makes with the SEC from time to time. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Tables Follow)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0952b3c99ed2481196753d8800680cd3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March  31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,104&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,832&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,268&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,936&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,268)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,936)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(734)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,942)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,670)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,676)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend due to Class B warrant price reset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,239)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,915)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders- basic and diluted </font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding-basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,751&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three  months ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,676)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,723)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,229)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,444)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,041&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,364)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,958&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,702&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,660&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,427&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,586&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,344&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,881&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,878&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,514&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,344&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,710&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,646&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,723&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,625&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,176&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58; </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,283&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,877&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,870&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,970&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,023&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, including accretion, net of discount</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,139&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,911&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,764&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,714&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,412&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,625&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,176&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Glenn Schulman, PharmD, MPH (corporate) </font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">VP, Investor Relations &#38; Corporate Communications</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:99%">glenn.schulman&#64;x4pharma.com </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:99%">(203) 494-7411</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Daniel Ferry  (investors)   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                     </font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Managing Director, LifeSci Advisors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                           </font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">daniel&#64;lifesciadvisors.com</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                       </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(617) 430-7576  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                           </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">M&#243;nica Rouco Molina, Ph.D. (media)</font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Account Supervisor, LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">mroucomolina&#64;lifescicomms.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20220512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8a82036e-c8b1-4aea-9b6e-232a1886b11a,g:b5d90bc6-920a-4dc4-9b65-22e0889bdd64-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20220512" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20220512">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20220512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8a82036e-c8b1-4aea-9b6e-232a1886b11a,g:b5d90bc6-920a-4dc4-9b65-22e0889bdd64-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressAddressLine1_8ed647c1-440a-4661-a86f-bcbf88ab62e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_43fe6d09-95a6-467f-881c-6650918f9f5c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f0908c22-d6fb-48d8-9bdd-383e26052bf1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d0375131-d5f9-487f-88b3-ed2363270d91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_57b91aef-012b-40f8-9d57-b975060e618d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f23752b2-5154-4bbf-8118-08c3f3899068_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_91f5152b-0eab-4049-a4c0-b0583569f096_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_21a02bf2-d201-43f5-ab0b-691572992f69_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8119a90d-e479-4cd6-8755-d1985103fb8e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2a99ac3b-d685-4fdc-95bd-b7e1341f19d3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c50d7899-bc6d-496d-97d2-3d06e1f3a6e4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4ff46b50-fa88-41b5-9f6c-6b6e2fb30cb2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_65d19914-5d14-402e-a6eb-eed5a833d85c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d3373f88-7036-4b80-b6ff-25ce1f63b413_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_6ce28f4a-bcdf-4699-b30e-8268131f99ef_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_398472ec-1af7-4229-8071-e3af5196ee29_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_31bade40-27a2-4303-a285-b9524bc82ef2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bae4576d-1d8d-40d5-a7a9-e5f46efd0a33_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_0460440c-a008-48f2-b90b-aa67f3d7b1c9_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5503ccc2-d995-430b-aa00-d5d4a3fedbb6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b8334175-d099-4105-989d-e9f761e5d2d2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c1292332-6bd2-438e-9f8d-0203f9d4a0b8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_81488ace-0387-4874-a48a-86810dfbb27d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f1add02d-fa4f-476b-b468-d3a3955fbf36_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20220512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8a82036e-c8b1-4aea-9b6e-232a1886b11a,g:b5d90bc6-920a-4dc4-9b65-22e0889bdd64-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20220512.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_12e6cbd4-7fff-45df-ab24-0d5e7ee4701e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_DocumentType_12e6cbd4-7fff-45df-ab24-0d5e7ee4701e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_09d86e76-ef4f-4786-ab9e-ee1968016c8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_DocumentPeriodEndDate_09d86e76-ef4f-4786-ab9e-ee1968016c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_949b1f55-9b7a-4f6f-8cc6-b1886660d6c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityRegistrantName_949b1f55-9b7a-4f6f-8cc6-b1886660d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0fd19270-dee6-4c97-bf39-c38b53f7349b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0fd19270-dee6-4c97-bf39-c38b53f7349b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a2f8d5d1-49e0-4194-a1e6-6af9d6884e3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityFileNumber_a2f8d5d1-49e0-4194-a1e6-6af9d6884e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_34edff75-1acc-48ad-867b-b0bde79894e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityTaxIdentificationNumber_34edff75-1acc-48ad-867b-b0bde79894e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6003877b-1886-482b-8a51-d219c6311829" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityAddressAddressLine1_6003877b-1886-482b-8a51-d219c6311829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d57f177b-bc73-4e85-91ca-329048a2893a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityAddressAddressLine2_d57f177b-bc73-4e85-91ca-329048a2893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3ea5aed1-b89e-4222-b2e8-387401916ab4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityAddressCityOrTown_3ea5aed1-b89e-4222-b2e8-387401916ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_809e2c11-7d38-4829-a5be-6b29a1c27316" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityAddressStateOrProvince_809e2c11-7d38-4829-a5be-6b29a1c27316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f4a09445-b79f-4c8b-8a04-c829e64c3187" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityAddressPostalZipCode_f4a09445-b79f-4c8b-8a04-c829e64c3187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a720c9bf-916e-4291-b841-408973237ca8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_CityAreaCode_a720c9bf-916e-4291-b841-408973237ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4b6ffdf8-5506-4c60-b8ea-3d20580fdd61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_LocalPhoneNumber_4b6ffdf8-5506-4c60-b8ea-3d20580fdd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_97e09268-2711-43ae-99ae-2d30afd6d50d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_WrittenCommunications_97e09268-2711-43ae-99ae-2d30afd6d50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fbf7d0af-93f9-490e-9a66-c6ae3b965872" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_SolicitingMaterial_fbf7d0af-93f9-490e-9a66-c6ae3b965872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b830d762-4719-450a-8887-1e5273c5f8b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_PreCommencementTenderOffer_b830d762-4719-450a-8887-1e5273c5f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3811bb1f-6a5a-4feb-b9e4-cf828e25f496" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3811bb1f-6a5a-4feb-b9e4-cf828e25f496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2e9bc10a-5a1e-4460-80f3-c34eba81172e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_Security12bTitle_2e9bc10a-5a1e-4460-80f3-c34eba81172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bb11607a-8d85-49a1-9d3a-bfd7bb585aef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_TradingSymbol_bb11607a-8d85-49a1-9d3a-bfd7bb585aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_caf8d497-06d5-4a64-bcf5-577e1064f3d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_SecurityExchangeName_caf8d497-06d5-4a64-bcf5-577e1064f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a2f3426-04ac-45df-92ac-fcb79bfc0b7c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a2f3426-04ac-45df-92ac-fcb79bfc0b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6c499d17-f158-40a7-96da-df5ddd9c2756" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityExTransitionPeriod_6c499d17-f158-40a7-96da-df5ddd9c2756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a14ad1bc-bee7-4254-b40d-2b9e826dd1ca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_EntityCentralIndexKey_a14ad1bc-bee7-4254-b40d-2b9e826dd1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c6e44e74-1c64-424a-9b91-af92ee3fd6ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08ab0369-4da4-46ef-a081-60fe8b51a54e" xlink:to="loc_dei_AmendmentFlag_c6e44e74-1c64-424a-9b91-af92ee3fd6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>x4logoa.jpg
<TEXT>
begin 644 x4logoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI=&-H($)U
M8VML97D   60 P "    %   $*:0!  "    %   $+J2D0 "     S,Q  "2
MD@ "     S,Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(P.C R.C U(#$W.C4W.C,Q #(P,C Z,#(Z
M,#4@,3<Z-3<Z,S$   !- &D = !C &@ ( !" '4 8P!K &P 90!Y    _^$+
M(&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D
M9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,C M,#(M,#54,3<Z-3<Z,S$N
M,S$R/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M
M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX\<F1F.FQI/DUI=&-H($)U8VML97D\+W)D9CIL:3X\+W)D9CI397$^
M#0H)"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&
M/CPO>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K
M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5
M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*
M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@ 10!? P$B  (1 0,1 ?_$ !\   $% 0$!
M 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$"
M P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G
M*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%
MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35
MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MC_/6NH\$>'.5U2\7I_J$([_WO\*Q?">@?VO?[YR/LUN07YY;OBO4XT"(%10
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M,XZU4T6&2WT*RAF4K(D"JRGL<5>KCJ3<GJ>E1I1IQT04445F;A1110 4444
2&*,444 )BC:*** %HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140434409170152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>xfor-20220512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20220512.xsd" xlink:type="simple"/>
    <context id="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY180L2ZyYWc6MjEyMTU5MmI5YTk0NDc5MzkyODk4YmVhZDc4ZThiNGIvdGFibGU6MGEzNDlmMjU2NTM4NDQ3MWE2ZGU2NjAyODVjYjQ2MTcvdGFibGVyYW5nZTowYTM0OWYyNTY1Mzg0NDcxYTZkZTY2MDI4NWNiNDYxN18wLTEtMS0xLTMzMTEy_70f1796f-a4b8-4743-b847-06a781846e2a">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY180L2ZyYWc6MjEyMTU5MmI5YTk0NDc5MzkyODk4YmVhZDc4ZThiNGIvdGFibGU6MGEzNDlmMjU2NTM4NDQ3MWE2ZGU2NjAyODVjYjQ2MTcvdGFibGVyYW5nZTowYTM0OWYyNTY1Mzg0NDcxYTZkZTY2MDI4NWNiNDYxN18xLTEtMS0xLTMzMTEy_83275463-635f-46c6-8e46-6c8645c2629f">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6YWFmZDgyODNlMWRkNGM4YjhlZWQ4MGUwNDlkZDgxZmEvdGFibGVyYW5nZTphYWZkODI4M2UxZGQ0YzhiOGVlZDgwZTA0OWRkODFmYV8wLTEtMS0xLTMzMTEy_0a007099-9ea7-4cde-a28e-e0bb2d3aaeec">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8yMTg_dfb70470-de11-44fc-82fd-1d17920887c8">2022-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6Y2Q4Y2VhODMxNzI1NDg1OTg5NDJiNzZmMzAwNGYxMzcvdGFibGVyYW5nZTpjZDhjZWE4MzE3MjU0ODU5ODk0MmI3NmYzMDA0ZjEzN18xLTAtMS0xLTMzMTEy_17e7ccc5-9752-42fc-a7e3-a4966410e006">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTAtMS0xLTMzMTEy_7f6c8c9b-bb62-4fe8-94d6-03cba294e536">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTItMS0xLTMzMTEy_b6b8c584-b2ec-4934-b3ce-93722dabe2ef">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGFlYmY1MjVjMzIyNDI2MjhhNzdhZDVjMDliZWE1NzQvdGFibGVyYW5nZTo0YWViZjUyNWMzMjI0MjYyOGE3N2FkNWMwOWJlYTU3NF8wLTQtMS0xLTMzMTEy_c0f6a93f-d58e-4400-8711-41311e87200e">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8wLTAtMS0xLTMzMTEy_c53758af-a876-4ae7-ab4b-55231a56bf4a">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8wLTEtMS0xLTMzMTEy_d3a58ebb-604a-440e-8d5f-ce3740fed585">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTAtMS0xLTMzMTEy_88d392c7-f4ba-4c06-937d-01fb8e50a9b8">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTEtMS0xLTMzMTEy_05d866ee-dd72-4650-989b-df1caa052565">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NGIzZTYxNzFlNzllNDgwZTgwNjdkYjUyMGE5MzZkZmYvdGFibGVyYW5nZTo0YjNlNjE3MWU3OWU0ODBlODA2N2RiNTIwYTkzNmRmZl8xLTMtMS0xLTMzMTEy_8278fd03-b91b-4531-a6cf-8a9106461dad">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDYy_7a42f1db-4284-4d6b-8c4e-854c971134b5">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDYz_aae65245-24ee-483d-832b-7062f15cb5a3">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY5_957a1602-3479-4493-98a6-2f341f05977c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcx_1d3b9dca-04ea-4dcd-8f00-e2ae26a8e24b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcy_8c991615-c481-4558-ab7b-63edda2aa8e2">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY2_70ba0d4c-663c-4c62-93f6-b33e3a656dfc">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTAtMS0xLTMzMTEy_188a330f-d78f-4bf3-98b2-f03f38fdb5b9">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTItMS0xLTMzMTEy_a4286795-9e96-4931-bcac-7c2849aa5812">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGFibGU6NjE1ZTZjZjc1NDBmNDA5MGFmNjU5MmQxYTU1NWQxN2YvdGFibGVyYW5nZTo2MTVlNmNmNzU0MGY0MDkwYWY2NTkyZDFhNTU1ZDE3Zl8xLTQtMS0xLTMzMTEy_dd605944-d812-4784-8000-cdc00a23691b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDY3_1cbf4261-7246-4bf2-9e15-67ed2d3d17ea">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlNGVlNzIwZDNlYjQyZGViMDMzYTkzNDViMDMxY2RjL3NlYzphZTRlZTcyMGQzZWI0MmRlYjAzM2E5MzQ1YjAzMWNkY18xL2ZyYWc6M2QwYjU0ZWI2ZGU1NDNjMjg1NTJmMzRhNjU1OGQzNmIvdGV4dHJlZ2lvbjozZDBiNTRlYjZkZTU0M2MyODU1MmYzNGE2NTU4ZDM2Yl8xNDcz_f2183b9d-a230-4e75-ae14-1db2c1e61043">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;%!+ 0(4 Q0    ( !9 K%1\ %*Y[@   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !9 K%297)PC$ 8  )PG
M   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ %D"L5%)0FU1C!   ;!$  !@              ("!#0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !9 K%2?H!OPL0(  .(,
M   -              "  :8,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M%D"L5)>*NQS     $P(   L              ( !@@\  %]R96QS+RYR96QS
M4$L! A0#%     @ %D"L5*K$(A8S 0  (@(   \              ( !:Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !9 K%0D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( !9 K%1ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20220512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20220512.htm">xfor-20220512.htm</File>
    <File>a991pressreleasedatedmay12.htm</File>
    <File>xfor-20220512.xsd</File>
    <File>xfor-20220512_lab.xml</File>
    <File>xfor-20220512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20220512.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xfor-20220512.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20220512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20220512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20220512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20220512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220512.htm",
      "contextRef": "i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220512.htm",
      "contextRef": "i9a3fdcde195b4721aaffe4e47c8b95ed_D20220512-20220512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-22-013956-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-013956-xbrl.zip
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M"%23.864U2NZ-(7'#F2J("6N*Y")&(P5J(R%UX/<,78 %=CA.,6+0QA)VJ*
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M-:@H&L'?<?W7 -$-\=)$D0,^^%=EX+ZU.DS[-)3IN#I-ZE4L:UI&D3:T&8P
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M_)S1OV/YREC^[3J6^TI@,%L-,-<M@36P*[!E2O<540D1EDD5192VJ8E58H$
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MI>=6=W1G?Z\'=76G]VW4:D(_)]]&+KT1RZ1.$^;4@[\3T-SV6XI3/;MHG;1
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M-GWO]D'=OK\D\3[";4KX3X;$YA_%&<2%]*@D(F(R&_S&,SE7T\KGHUPU81Z
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M507A8I^9;P;71=9@EPI=RS&R?@E57H:W1?@1^]R,FJ E*$D@"@Q :8D!&"
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M-3$R+GAS9%!+ 0(4 Q0    ( !9 K%0(A,DUV0H  %QE   5
M  "  2DW  !X9F]R+3(P,C(P-3$R7VQA8BYX;6Q02P$"% ,4    "  60*Q4
MI_1M1P,'  !Q-0  %0              @ $U0@  >&9O<BTR,#(R,#4Q,E]P
<<F4N>&UL4$L%!@     %  4 4 $  &M)      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
